Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours

X
Trial Profile

A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EVT 801 (Primary)
  • Indications Colon cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Kazia Therapeutics
  • Most Recent Events

    • 01 May 2024 According to a Kazia Therapeutics media release, the company plans to share final results from this trial at an upcoming scientific conference in the second half of 2024.
    • 01 May 2024 Results published in the Media Release
    • 01 May 2024 According to a Kazia Therapeutics media release, the Safety Review Team (SRT) of this trial concluded that the stage I of phase I study completed with primary and secondary objectives of stage 1 of the trial have successfully been met. The SRT has reviewed all preliminary (non-final) safety and pharmacokinetic (PK) data, and unanimously agreed that the maximal tolerated dose (MTD) has been reached at 500mg twice a day (BID). 400mg BID was identified as the starting recommended phase 2 dose.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top